Base de dados : MEDLINE
Pesquisa : E02.319.267.082.500 [Categoria DeCS]
Referências encontradas : 51237 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5124 ir para página                         

  1 / 51237 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29214792
[Au] Autor:Park M; Kim M; Park J; Cho J
[Ad] Endereço:Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea.
[Ti] Título:Life-Threatening Thrombocytopenia Following Intravenous Contrast Media Infusion.
[So] Source:Yonsei Med J;59(1):158-161, 2018 Jan.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:Radiocontrast media-induced acute severe thrombocytopenia is a very rare complication and potentially life-threatening. Here, we report the case of a 63-year-old male patient with severe acute thrombocytopenia following first exposure to intravenous non-ionic contrast media without immediate allergic reactions. His platelet count dropped from 107000/µL to 2000/µL after six hours of radiocontrast infusion. After administration of corticosteroid and transfusion of platelet concentrates, the platelet count returned gradually to normal within 5 days. To the best of our knowledge, non-ionic contrast media-induced isolated acute severe thrombocytopenia following no signs or symptoms of immediate allergic reaction has never been described.
[Mh] Termos MeSH primário: Meios de Contraste/administração & dosagem
Meios de Contraste/efeitos adversos
Trombocitopenia/etiologia
[Mh] Termos MeSH secundário: Doença Aguda
Administração Intravenosa
Seres Humanos
Infusões Intravenosas
Masculino
Meia-Idade
Contagem de Plaquetas
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Contrast Media)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2018.59.1.158


  2 / 51237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29200855
[Au] Autor:Gerstenhaber JA; Barone FC; Marcinkiewicz C; Li J; Shiloh AO; Sternberg M; Lelkes PI; Feuerstein G
[Ad] Endereço:Department of Bioengineering, College of Engineering, Temple University, Philadelphia, PA.
[Ti] Título:Vascular thrombus imaging in vivo via near-infrared fluorescent nanodiamond particles bioengineered with the disintegrin bitistatin (Part II).
[So] Source:Int J Nanomedicine;12:8471-8482, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:The aim of this feasibility study was to test the ability of fluorescent nanodiamond particles (F-NDP) covalently conjugated with bitistatin (F-NDP-Bit) to detect vascular blood clots in vivo using extracorporeal near-infrared (NIR) imaging. Specifically, we compared NIR fluorescence properties of F-NDP with N-V (F-NDP ) and N-V-N color centers and sizes (100-10,000 nm). Optimal NIR fluorescence and tissue penetration across biological tissues (rat skin, porcine axillary veins, and skin) was obtained for F-NDP with a mean diameter of 700 nm. Intravital imaging (using in vivo imaging system [IVIS]) in vitro revealed that F-NDP -loaded glass capillaries could be detected across 6 mm of rat red-muscle barrier and 12 mm of porcine skin, which equals the average vertical distance of a human carotid artery bifurcation from the surface of the adjacent skin (14 mm). In vivo, feasibility was demonstrated in a rat model of occlusive blood clots generated using FeCl in the carotid artery bifurcation. Following systemic infusions of F-NDP -Bit (3 or 15 mg/kg) via the external carotid artery or femoral vein (N=3), presence of the particles in the thrombi was confirmed both in situ via IVIS, and ex vivo via confocal imaging. The presence of F-NDP in the vascular clots was further confirmed by direct counting of fluorescent particles extracted from clots following tissue solubilization. Our data suggest that F-NDP -Bit associate with vascular blood clots, presumably by binding of F-NDP -Bit to activated platelets within the blood clot. We posit that F-NDP -Bit could serve as a noninvasive platform for identification of vascular thrombi using NIR energy monitored by an extracorporeal device.
[Mh] Termos MeSH primário: Bioengenharia/métodos
Diagnóstico por Imagem
Desintegrinas/química
Raios Infravermelhos
Nanodiamantes/química
Peptídeos/química
Trombose/diagnóstico
[Mh] Termos MeSH secundário: Animais
Artérias Carótidas/patologia
Modelos Animais de Doenças
Desintegrinas/administração & dosagem
Fluorescência
Seres Humanos
Infusões Intravenosas
Masculino
Peptídeos/administração & dosagem
Ratos Sprague-Dawley
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Disintegrins); 0 (Nanodiamonds); 0 (Peptides); 124123-27-9 (bitistatin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S146946


  3 / 51237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28749092
[Au] Autor:Andrade C
[Ad] Endereço:Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India. candrade@psychiatrist.com.
[Ti] Título:Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?
[So] Source:J Clin Psychiatry;78(7):e852-e857, 2017 Jul.
[Is] ISSN:1555-2101
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ketamine, administered in subanesthetic doses, is an effective off-label treatment for severe and even treatment-refractory depression; however, despite dozens of studies across nearly 2 decades of research, there is no definitive guidance on matters related to core practice issues. METHODS: This article presents a qualitative review and summary about what is known about ketamine dosing, rate of administration, route of administration, duration of treatment, and frequency of sessions. RESULTS: Ketamine is most commonly administered in the dose of 0.5 mg/kg, but some patients may respond to doses as low as 0.1 mg/kg, and others may require up to 0.75 mg/kg. The ketamine dose is conventionally administered across 40 minutes; however, safety and efficacy have been demonstrated in sessions ranging between 2 and 100 minutes in duration. Bolus administration is safe and effective when the drug is administered intramuscularly or subcutaneously. Whereas the intravenous route is the most commonly employed, safety and efficacy have been described with other routes of administration, as well; these include oral, sublingual, transmucosal, intranasal, intramuscular, and subcutaneous routes. Patients may receive a single session of treatment or a course of treatment during the acute phase, and treatment may rarely be continued for weeks to years to extend and maintain treatment gains in refractory cases. When so extended, the ideal frequency is perhaps best individualized wherein ketamine is dosed a little before the effect of the previous session is expected to wear off. CONCLUSIONS: There is likely to be a complex interaction between ketamine dose, session duration, route of administration, frequency of administration, and related practice. Until definitive studies comparing different doses, rates of administration, routes of administration, and other considerations are conducted, firm recommendations are not possible. From the point of view of clinical practicability, subcutaneous, intranasal, and oral ketamine warrant further study. If domiciliary treatment is considered, the risk of abuse must be kept in mind.
[Mh] Termos MeSH primário: Antidepressivos/administração & dosagem
Transtorno Depressivo Maior/tratamento farmacológico
Ketamina/administração & dosagem
[Mh] Termos MeSH secundário: Antidepressivos/efeitos adversos
Relação Dose-Resposta a Droga
Esquema de Medicação
Seres Humanos
Infusões Intravenosas
Injeções Intramusculares
Injeções Subcutâneas
Ketamina/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antidepressive Agents); 690G0D6V8H (Ketamine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE


  4 / 51237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27777173
[Au] Autor:Poole DS; Doorenweerd N; Plomp JJ; Mahfouz A; Reinders MJT; van der Weerd L
[Ad] Endereço:Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands. Electronic address: D.Poole@lumc.nl.
[Ti] Título:Continuous infusion of manganese improves contrast and reduces side effects in manganese-enhanced magnetic resonance imaging studies.
[So] Source:Neuroimage;147:1-9, 2017 Feb 15.
[Is] ISSN:1095-9572
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The ability to administer systemically high doses of manganese as contrast agent while circumventing its toxicity is of particular interest for exploratory MRI studies of the brain. Administering low doses either repeatedly or continuously over time has been shown to enable the acquisition of satisfactory MRI images of the mouse brain without apparent side effects. Here we have systematically compared the obtained MRI contrast and recorded potential systemic side effects such as stress response and muscle strength impairment in relation to the achieved contrast. We show in mice that administering MnCl via osmotic infusion pumps allows for a side-effect free delivery of a high cumulative dose of manganese chloride (480mg/kg bodyweight in 8 days). High contrast in MRI was achieved while we did not observe the weight loss or distress seen in other studies where mice received manganese via fractionated intraperitoneal injections of lower doses of manganese. As the normal daily conduct of the mice was not affected, this new manganese delivery method might be of particular use to study brain activity over several days. This may facilitate the phenotyping of new transgenic mouse models, the study of chronic disease models and the monitoring of changes in brain activity in long-term behavioral studies.
[Mh] Termos MeSH primário: Cloretos/administração & dosagem
Cloretos/farmacologia
Meios de Contraste/administração & dosagem
Meios de Contraste/farmacologia
Imagem por Ressonância Magnética/métodos
Compostos de Manganês/administração & dosagem
Compostos de Manganês/farmacologia
[Mh] Termos MeSH secundário: Animais
Cloretos/efeitos adversos
Meios de Contraste/efeitos adversos
Corticosterona/sangue
Aumento da Imagem
Bombas de Infusão
Infusões Intravenosas
Injeções Intraperitoneais
Masculino
Compostos de Manganês/efeitos adversos
Camundongos
Camundongos Endogâmicos C57BL
Força Muscular/efeitos dos fármacos
Estresse Psicológico/induzido quimicamente
Estresse Psicológico/psicologia
Perda de Peso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chlorides); 0 (Contrast Media); 0 (Manganese Compounds); QQE170PANO (manganese chloride); W980KJ009P (Corticosterone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  5 / 51237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29403337
[Au] Autor:Umunakwe OC; Herren D; Kim SJ; Kohanim S
[Ad] Endereço:Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.
[Ti] Título:Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature.
[So] Source:Digit J Ophthalmol;23(4):18-21, 2017.
[Is] ISSN:1542-8958
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bisphosphonates have become a commonly used class of medications to treat osteoporosis and other bone diseases. Zoledronate (zoledronic acid) can be dosed annually via intravenous infusion, making it an appealing option for patients and physicians. We report the case of a 68-year-old woman who developed severe, unilateral, ocular inflammation, including corneal endotheliitis, anterior uveitis with hyphema, scleritis, and orbital inflammation beginning 12 hours after receiving her first zoledronate infusion. Symptoms escalated but ultimately resolved with topical steroids and high-dose systemic corticosteroids. To our knowledge, this is the first report of unilateral diffuse inflammation of the eye and orbit, including corneal inflammation developing within 12 hours of a first zoledronate infusion.
[Mh] Termos MeSH primário: Difosfonatos/efeitos adversos
Imidazóis/efeitos adversos
Doenças Orbitárias/induzido quimicamente
Osteoporose/tratamento farmacológico
Uveíte Anterior/induzido quimicamente
[Mh] Termos MeSH secundário: Doença Aguda
Idoso
Conservadores da Densidade Óssea/administração & dosagem
Conservadores da Densidade Óssea/efeitos adversos
Difosfonatos/administração & dosagem
Feminino
Seres Humanos
Imidazóis/administração & dosagem
Inflamação/induzido quimicamente
Inflamação/diagnóstico
Infusões Intravenosas
Doenças Orbitárias/diagnóstico
Tomografia Computadorizada por Raios X
Uveíte Anterior/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Diphosphonates); 0 (Imidazoles); 6XC1PAD3KF (zoledronic acid)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE
[do] DOI:10.5693/djo.02.2017.08.002


  6 / 51237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Roesler, Rafael
Texto completo
[PMID]:28452904
[Au] Autor:Marchezan J; Becker M; Schwartsmann G; Ohlweiler L; Roesler R; Renck LB; Gonçalves MMM; Ranzan J; Riesgo RDS
[Ad] Endereço:*Postgraduate Program in Child and Adolescent Health, School of Medicine, Federal University of Rio Grande do Sul; †Department of Pediatrics, Child Neurology Unit, Hospital de Clínicas de Porto Alegre; ‡Department of Internal Medicine, School of Medicine, Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), §Department of Pharmacology, Institute for Basic Health Sciences, Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), and ∥Department of Pediatrics, Child Neurology Unit, Postgraduate Program in Child and Adolescent Health, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
[Ti] Título:A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism.
[So] Source:Clin Neuropharmacol;40(3):108-112, 2017 May/Jun.
[Is] ISSN:1537-162X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of this study was to evaluate the efficacy, safety, and tolerability of gastrin-releasing peptide (GRP) compared with placebo in autism spectrum disorder symptoms. METHODOLOGY: This is a randomized, double-blind, placebo-controlled crossover trial using GRP 160 pmol/kg for 4 consecutive days in 10 children with autism. Outcomes were measured by the Aberrant Behavior Checklist (ABC) scale. RESULTS: All participants were boys, aged between 4 and 9 years. There was a reduction in the scores of the ABC range and its subscales after use GRP and placebo. The reduction was more prominent with GRP, particularly in the subscale "hyperactivity and noncompliance," but there was no statistical difference between the results (P = 0.334). After a week of infusion, 5 children showed improvement of 25% or greater in the total score of the ABC scale with GRP use and 2 with placebo use; however, there was no statistical difference (P = 0.375). There were no adverse effects, changes in vital signs, or laboratory abnormalities associated with the use of GRP. CONCLUSIONS: The results of this study, despite the small sample size, reinforce previous data on the safety of the GRP in short-term use. There is a need for further research with other designs and a larger sample size to evaluate the efficacy and safety of GRP in children with autism.
[Mh] Termos MeSH primário: Transtorno do Espectro Autista/tratamento farmacológico
Comportamento Infantil/efeitos dos fármacos
Peptídeo Liberador de Gastrina/uso terapêutico
Psicotrópicos/uso terapêutico
[Mh] Termos MeSH secundário: Antiulcerosos/uso terapêutico
Anticonvulsivantes/efeitos adversos
Anticonvulsivantes/uso terapêutico
Antipsicóticos/efeitos adversos
Antipsicóticos/uso terapêutico
Transtorno do Espectro Autista/fisiopatologia
Transtorno do Espectro Autista/psicologia
Criança
Pré-Escolar
Terapia Combinada/efeitos adversos
Estudos Cross-Over
Manual Diagnóstico e Estatístico de Transtornos Mentais
Método Duplo-Cego
Quimioterapia Combinada/efeitos adversos
Seguimentos
Peptídeo Liberador de Gastrina/administração & dosagem
Peptídeo Liberador de Gastrina/efeitos adversos
Seres Humanos
Infusões Intravenosas
Masculino
Omeprazol/uso terapêutico
Escalas de Graduação Psiquiátrica
Psicotrópicos/administração & dosagem
Psicotrópicos/efeitos adversos
Reprodutibilidade dos Testes
Índice de Gravidade de Doença
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Anticonvulsants); 0 (Antipsychotic Agents); 0 (Psychotropic Drugs); 80043-53-4 (Gastrin-Releasing Peptide); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1097/WNF.0000000000000213


  7 / 51237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29293200
[Au] Autor:de Freitas Floriano CM; Machado Avelar AF; Sorgini Peterlini MA
[Ad] Endereço:Escola Paulista de Enfermagem, Universidade Federal de São Paulo, São Paulo, Brazil (Drs Machado Avelar and Sorgini Peterlini and Ms de Freitas Floriano). Claudia Maria de Freitas Floriano, MSc, is a pediatric emergency nurse at the Escola Paulista de Enfermagem of the Universidade Federal de São Paulo, in São Paulo, Brazil. Ariane Ferreira Machado Avelar, PhD, MSc, RN, is an adjunct professor at the Escola Paulista de Enfermagem of the Universidade Federal de São Paulo in São Paulo, Brazil. Maria Angélica Sorgini Peterlini, PhD, MSc, RN, is an associate professor at the Escola Paulista de Enfermagem of the Universidade Federal de São Paulo in São Paulo, Brazil.
[Ti] Título:Difficulties Related to Peripheral Intravenous Access in Children in an Emergency Room.
[So] Source:J Infus Nurs;41(1):66-72, 2018 Jan/Feb.
[Is] ISSN:1539-0667
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This prospective study examined the characteristics of children admitted to a pediatric emergency department and the factors that influenced the successful establishment of peripheral intravenous (IV) access. Descriptive and correlational analysis was completed using a convenience sample of 89 patients. Peripheral IV access was successful in 95.7% of the children, and the first attempt at insertion was successful in 53% of the procedures. Factors influencing the success of peripheral IV access were the patient's gender, skin color, presence of difficult-to-see veins, small veins, presence of fever, and a lack of palpable veins.
[Mh] Termos MeSH primário: Cateterismo Periférico/efeitos adversos
Serviço Hospitalar de Emergência
Veias/anormalidades
[Mh] Termos MeSH secundário: Administração Intravenosa/métodos
Adolescente
Fatores Etários
Cateterismo Periférico/instrumentação
Criança
Pré-Escolar
Grupos de Populações Continentais
Feminino
Seres Humanos
Lactente
Recém-Nascido
Infusões Intravenosas/instrumentação
Masculino
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE
[do] DOI:10.1097/NAN.0000000000000262


  8 / 51237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29293195
[Au] Autor:Hadaway L
[Ad] Endereço:Lynn Hadaway Associates, Inc, Milner, Georgia. Lynn Hadaway, MEd, RN-BC, CRNI®, is president of Lynn Hadaway Associates, Inc, and has more than 40 years' experience as an infusion nurse, educator, and consultant. She holds a master's degree in education, as well as certification in professional staff development and infusion nursing. She has published extensively on infusion topics in numerous journals.
[Ti] Título:Stopcocks for Infusion Therapy: Evidence and Experience.
[So] Source:J Infus Nurs;41(1):24-34, 2018 Jan/Feb.
[Is] ISSN:1539-0667
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Stopcocks have been used for decades to deliver infusion therapy in patients of all ages and in all health care settings. During the past 20 years, a growing number of studies have validated concern about the risk of the open lumen allowing intraluminal contamination. Additional studies highlight fluid flow dynamics associated with stopcocks. This integrative literature review and clinician practice survey analyzes the published evidence and reports of actual practices with stopcocks, and raises issues about practice changes that could reduce these risks.
[Mh] Termos MeSH primário: Contaminação de Equipamentos/prevenção & controle
Infusões Intravenosas/métodos
Padrões de Prática Médica
[Mh] Termos MeSH secundário: Administração Intravenosa/efeitos adversos
Infecção Hospitalar/microbiologia
Infecção Hospitalar/prevenção & controle
Seres Humanos
Infusões Intravenosas/efeitos adversos
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE
[do] DOI:10.1097/NAN.0000000000000258


  9 / 51237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386437
[Au] Autor:Nagasato A; Nakamura M; Kamimura H
[Ad] Endereço:Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University.
[Ti] Título:[Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants].
[So] Source:Yakugaku Zasshi;138(2):237-242, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: Methylxanthine is widely administered for the treatment of apnea of prematurity in many countries, and previous reports have clearly established that caffeine is effective for the treatment of apnea of prematurity. In Japan, caffeine has been available since December 2014. Thus, we compared the efficacy and safety of caffeine with that of aminophylline in our hospital. There was no significant difference between the caffeine group and aminophylline group regarding the characteristics of the study patients. The mean efficacy rate from day 1 to day 10 was 89.5% in the caffeine group, and 81.9% in the aminophylline group, although the rate of improvement in apnea episodes each day from day 1 to day 10 was not significantly different between the two groups. On the other hand, the adverse event rates in the caffeine group and the aminophylline group were 70.6% and 75.0%, respectively. No significant difference was observed in the adverse event rates between the two groups. Moreover, suspected abdominal distension due to the drug administration was more frequently observed with the aminophylline group. Our findings indicate that caffeine is as effective as aminophylline, while it is superior to aminophylline regarding its overall safety.
[Mh] Termos MeSH primário: Aminofilina/administração & dosagem
Apneia/tratamento farmacológico
Cafeína/administração & dosagem
Recém-Nascido Prematuro
[Mh] Termos MeSH secundário: Administração Oral
Aminofilina/efeitos adversos
Apneia/etiologia
Cafeína/efeitos adversos
Feminino
Seres Humanos
Recém-Nascido
Infusões Intravenosas
Masculino
Segurança
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
27Y3KJK423 (Aminophylline); 3G6A5W338E (Caffeine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00144


  10 / 51237 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29400589
[Au] Autor:Clack C
[Ti] Título:Putting an End to Emergency Room Injection/Infusion Coding Confusion.
[So] Source:J AHIMA;87(9):60-2, 2016 09.
[Is] ISSN:1060-5487
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Codificação Clínica/normas
Serviço Hospitalar de Emergência
Infusões Intravenosas/classificação
Injeções/classificação
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:H
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE



página 1 de 5124 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde